IDEAYA Biosciences

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
IDEAYA Biosciences, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.Fineline Info & Tech (Flcube.com) provides you with comprehensive information about IDEAYA Biosciences, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML
CompanyDrug

InnoCare Doses First Patient in Registrational Phase III Head‑to‑Head Trial of Mesutoclax Versus Venetoclax – Challenging the Standard of Care in Treatment‑Naïve AML

InnoCare Pharma (HKG: 9969; SHA: 688428) announced today that the first patient has been dosed in the registrational Phase III head‑to‑head clinical trial of the Company's novel BCL2 inhibitor mesutoclax…

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer's Disease Diagnosis and Treatment

Eisai and Siemens Healthineers Sign Strategic Cooperation Agreement at CIIE – Advancing Precision Imaging in Alzheimer’s Disease Diagnosis and Treatment

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment
CompanyDeals

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
CompanyDeals

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849

Biocytogen's First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
CompanyDeals

Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences

CompanyDeals

Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program

CompanyDeals

MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer